Developer docs
API playgroundTry for free, no card

Search company profiles

iMEAN

Full company profile

uuid0009x8c

Namestring
iMEAN
Legal namestring
iMEAN
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToulouse, France
HQ citystring
Toulouse
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genome-scale metabolic modeling, digital organism simulation, systems biology consulting, bioinformatics services, metabolic engineering solutions
Industry4 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYAFABALAL
Digital Breeding & Bioinformatics Software (Breeding informatics, decision tools)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Seed Technologies (Genetic Engineering & Trait Development)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
Product category
Computational Biology Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Project-Based R&D Services
TypeProfessional Services
Description

iMEAN generates revenue through custom consulting and project-based services where it delivers tailor-made mathematical models, data analyses, and bioinformatics solutions to industrial and academic clients. Services are priced per project and include organism design, feasibility studies, consortia design, digital boost support, multi-omics integration, GWAS, and custom bioinformatics analyses.

imean-biotech.com
2Digital Organism Licensing / Model Delivery
TypeOne Time License
Description

iMEAN delivers genome-scale models (digital twins) as structured outputs, either as one-time deliverables or potentially as licensed models with ongoing support and updates. Models include genome-scale metabolic networks, kinetics models, regulatory networks, and multi-scale models embedded with cellular burden and protein secretion machinery.

imean-biotech.com
3Software and Web Platform Services
TypeProfessional Services
Description

iMEAN develops custom software applications, web interfaces, and genomic databases for clients, providing visualization tools, pathway maps, dashboards, and Pathway Tools-based web servers for model exploration.

imean-biotech.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Custom project-based pricing for Agriculture, Industrial Biotech, and Academic Research solutions
ModelOtherBilling cadenceMulti-year contract
Notes

iMEAN operates on a project-by-project basis with tailored service offerings. No standard pricing tiers are publicly disclosed. Contact form and direct email are used for quotes. The company delivers genome-scale models 4x faster and at half the cost of conventional approaches.

imean-biotech.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

iMEAN builds genome-scale mathematical models ("digital organisms") of living cells — bacteria, fungi, yeast, microalgae, and plants — using constraint-based modeling, multi-omics integration, regulatory network inference, and kinetics modeling. It sells these models together with feasibility studies, organism design, consortia design, and ongoing Digital Boost R&D support to industrial biotech, agriculture, cosmetics, food, and academic clients via project-based engagements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • R&D failure rate reduction of up to 30% and R&D time/cost savings of up to 50% through digital boost services
+3 more records
Product overview1 text field

iMEAN is a bioinformatics startup offering a unified biomodeling platform centered on 'digital organisms' — mathematical representations of complex molecular networks in living cells. The platform provides genome-scale metabolic models (GEMs), kinetics models, and regulatory network inference for academic research, agriculture, and industrial biotechnology applications. Services are delivered through four solution verticals: Agriculture, Industrial Biotechnology, Academic Research, and Custom Data Analyses. Key offerings include Organism Design (in silico combinatorial studies), Feasibility Studies, Consortia Design, and Digital Boost (ongoing R&D support). The platform also provides bioinformatics tools including genome assembly/annotation, protein design, pathway identification, and metabolic visualization through partnerships like SRI International's Pathway Tools.

Product and service6 records
1Agriculture Solutions
CategoryAgriculture
Description

Custom digital organism models and in silico analyses for agricultural R&D clients, including crop breeding, biocontrol, biostimulant, and plant-microbe interaction use cases. Used by crop science companies, plant breeders, and biocontrol developers.

2Industrial Biotechnology Solutions
CategoryIndustrial Biotechnology
Description

Custom digital organism models and bio-process modeling services for industrial biotech, bio-based chemicals, food ingredient, and cosmetics producers using microbial, fungal, or microalgae-based production platforms.

3Academic Research Solutions
CategoryAcademic Research
Description

Custom mathematical modeling and bioinformatics services for academic laboratories and public research institutions working on fundamental biology, drug discovery, plant biology, and environmental microbiology.

4Custom Data Analyses
CategoryCustom Data Analyses
Description

Tailored bioinformatics workflows combining modeling, biostatistics, and bioinformatics for organizations with specific analytical needs beyond standard service offerings.

5Digital Boost
CategoryOngoing R&D Support Service
Description

Ongoing R&D support service delivering daily dedicated modeling expertise and technical resources to client teams to reduce failure rates and accelerate bioprocess development.

6Feasibility Study
CategoryIn Silico Feasibility Analysis
Description

In silico feasibility analysis for biotech projects, modeling industrial scenarios to evaluate expected performance and identify bottlenecks before committing to wet-lab experimentation.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

iMEAN and New Wave Biotech partner to deliver an integrated modeling workflow combining upstream and downstream bioprocess insights, accelerating scalable bioprocess development. The joint offering simplifies and accelerates the path to scalable bioprocesses.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-21
Description

iMEAN joined the Ferments du Futur consortium dedicated to advancing research and innovation in fermented foods and biopreservation. iMEAN contributes expertise in mathematical modeling and Digital FoodTech solutions to accelerate R&D for healthy, sustainable food and the One Health value chain.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-14
Description

iMEAN and Micropep collaboration to advance sustainable agriculture by combining complementary expertise in predictive modeling and micropeptide technologies for crop protection and improvement.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-08-07
Description

iMEAN and Novobiom (Belgian biotech startup specializing in mycoremediation) collaborate to develop innovative bioremediation solutions for soil pollutants. iMEAN provides in silico design and optimization using fungal metabolic models, while Novobiom contributes its collection of fungi and enzyme cocktails for on-site depollution.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-07
Description

iMEAN is a spin-off of INRAE, having developed its technology during 10+ years of research at the institution. iMEAN continues to draw expertise from INRAE labs including ToxAlim (Metabolism & Xenobiotics team), LIPME, and RESTORE institute, and benefits from ongoing institutional support.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-06-02
Description

The iCORN project (€2M, France 2030 funded) combines iMEAN's systems biology models with Limagrain's breeding programs to accelerate development of drought-resistant maize varieties. iMEAN builds the most advanced mechanistic model of maize to improve genomic selection. This is a flagship multi-year partnership spanning 5 years with the goal of TRL 9.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-09-21
Description

iMEAN partnered with SRI International to integrate Pathway Tools software into its service offering, enabling iMEAN customers to access in silico models via web interfaces generated by SRI's Pathway Tools. This provides complete analysis pipelines including model construction, web interface setup, and IT maintenance.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-08-30
Description

iMEAN leads the construction of a genomic database and web interface for 1,000 food-grade microorganisms from LM-UGent's collection for Puratos, enabling identification of enzymes and metabolic pathways for innovative food ingredients. iMEAN provided bioinformatics expertise, software development, and metabolic analysis capabilities.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-01-31
Description

iMEAN provides Cambrium (Berlin-based synthetic biology startup developing protein-based biomaterials) with advanced mathematical models to accelerate strain engineering and scale-up. Cambrium's platform combines protein engineering, ML, and lab automation, which is complemented by iMEAN's high-predictive modeling.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-13
Description

iMEAN and L'Oréal published a joint paper in ASM journal on the genome of Sphingobium xenophagum from La Roche-Posay thermal springs. iMEAN provides in silico reconstruction of exotic microorganisms and bioinformatics tools for biodiversity exploration supporting L'Oréal's thermal water research and cosmetic ingredient discovery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-08-24
Description

Bayer Crop Science partners with iMEAN to use digital organisms of plants and plant pathogens to accelerate discovery of new environmentally friendly crop protection products. iMEAN's platform extracts biological insights from Bayer's experimental data on substances and supports design of innovative chemistry at early discovery stages.

Strategic tierMinorTypeOthersAnnounced on2021-07-01
Description

iMEAN joined BIOMED Alliance, the largest cluster of biomedical companies in Occitanie with over 80 member companies. The membership federates local actors to develop biotech business in France and across borders, with iMEAN contributing in silico tools for oncology and microbiota engineering.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-05-12
Description

iMEAN set up a modeling platform for Neoplants (Parisian biotech startup developing bioengineered ornamental plants for air pollution). iMEAN designs highly predictive plant models combining complex metabolic networks and plant biology expertise to support fast and successful bioengineering projects.

14EU Project DIVA
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-04-02
Description

iMEAN's 'Digital Seed' project was selected by EU Project DIVA for funding. The project aims to boost crop breeding through digital organisms. Over 350 SMEs applied to the DIVA Open Call with 255 proposals submitted.

imean-biotech.com
15TWB (Toulouse White Biotechnology)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-10-18
Description

iMEAN integrates the TWB ecosystem — a pre-industrial demonstrator in industrial biotechnology (UMS under INRAE, INSA, CNRS). TWB provides wet lab capabilities (Build, Test) complementing iMEAN's dry lab modeling (Design, Learn), enabling a Design-Build-Test-Learn cycle. The partnership was strengthened in 2021 to offer a combined service from dry lab to wet lab, and iMEAN's offices are located within TWB premises.

imean-biotech.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Israel-based company building cell-level computational models of the human immune system for drug discovery and development. Closely comparable as a model-as-a-service platform serving enterprise biotech/pharma customers.

TypeBroad incumbent
Description

Enzyme engineering company using computational and directed evolution approaches to develop industrial biocatalysts. Comparable as a computational biology company serving industrial biotech customers in pharmaceutical and food applications.

TypeEmerging player
Description

Synthetic biology platform combining AI with lab automation for DNA design and strain engineering workflows. Comparable as a bioinformatics/informatics platform for synbio customers, though more focused on DNA construct design.

TypeBroad incumbent
Description

Machine learning-driven drug discovery company building predictive models of disease from large-scale biological data. Comparable as a data/ML-led biology company, but focused on therapeutics rather than organism engineering.

TypeDirect peer
Description

US-based seed design company using AI and systems biology to develop high-performing crops (e.g., drought-resistant maize). Closest direct peer to iMEAN's Limagrain/iCORN work — both apply computational biology to crop improvement.

TypeEmerging player
Description

Cloud-based platform for biology R&D with LIMS, ELN, and molecular biology tools. Comparable as a life science informatics platform for biotech R&D teams, though broader and more horizontal than iMEAN's modeling-specific offering.

TypeBroad incumbent
Description

Computational chemistry and biology platform serving pharma and materials customers with physics-based simulation software. Comparable as a computational biology software vendor; broader scope (chemistry, materials) but similar enterprise SaaS model.

TypeBroad incumbent
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning. Comparable as a large-scale computational biology platform, though focused on pharma rather than industrial biotech and agriculture.

TypeBroad incumbent
Description

US-based organism engineering platform offering end-to-end synthetic biology services across industrial, ag, and pharma. Larger, broader offering than iMEAN's focused metabolic-modeling services, but overlapping on organism design and strain engineering.

10Amyris
TypeBroad incumbent
Description

Synthetic biology company engineering yeast strains for sustainable ingredient production. Comparable as a synbio company applying computational biology to industrial strain engineering, though now restructured and focused on ingredients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iMEAN

Computational Biology Servicesimean-biotech.com

iMEAN firmographics

Firmographics
Name
iMEAN
Legal name
iMEAN
Website
https://imean-biotech.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

iMEAN industry classification

Industry
Product category
Computational Biology Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYAFABALAL
Digital Breeding & Bioinformatics Software (Breeding informatics, decision tools)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Seed Technologies (Genetic Engineering & Trait Development)

Keywords

  • Genome-scale metabolic modeling
  • Digital organism simulation
  • Systems biology consulting
  • Bioinformatics services
  • Metabolic engineering solutions

Where iMEAN is headquartered

Location

Headquarters

HQ city
Toulouse
HQ country
France
HQ region
Europe

Offices2 records

Markets served

iMEAN business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Project-Based R&D Services: iMEAN generates revenue through custom consulting and project-based services where it delivers tailor-made mathematical models, data analyses, and bioinformatics solutions to industrial and academic clients. Services are priced per project and include organism design, feasibility studies, consortia design, digital boost support, multi-omics integration, GWAS, and custom bioinformatics analyses.
  2. Digital Organism Licensing / Model Delivery: iMEAN delivers genome-scale models (digital twins) as structured outputs, either as one-time deliverables or potentially as licensed models with ongoing support and updates. Models include genome-scale metabolic networks, kinetics models, regulatory networks, and multi-scale models embedded with cellular burden and protein secretion machinery.
  3. Software and Web Platform Services: iMEAN develops custom software applications, web interfaces, and genomic databases for clients, providing visualization tools, pathway maps, dashboards, and Pathway Tools-based web servers for model exploration.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for Agriculture, Industrial Biotech, and Academic Research solutions

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

iMEAN product offering

Product offering

Core offering

iMEAN builds genome-scale mathematical models ("digital organisms") of living cells — bacteria, fungi, yeast, microalgae, and plants — using constraint-based modeling, multi-omics integration, regulatory network inference, and kinetics modeling. It sells these models together with feasibility studies, organism design, consortia design, and ongoing Digital Boost R&D support to industrial biotech, agriculture, cosmetics, food, and academic clients via project-based engagements.

Product overview

iMEAN is a bioinformatics startup offering a unified biomodeling platform centered on 'digital organisms' — mathematical representations of complex molecular networks in living cells. The platform provides genome-scale metabolic models (GEMs), kinetics models, and regulatory network inference for academic research, agriculture, and industrial biotechnology applications. Services are delivered through four solution verticals: Agriculture, Industrial Biotechnology, Academic Research, and Custom Data Analyses. Key offerings include Organism Design (in silico combinatorial studies), Feasibility Studies, Consortia Design, and Digital Boost (ongoing R&D support). The platform also provides bioinformatics tools including genome assembly/annotation, protein design, pathway identification, and metabolic visualization through partnerships like SRI International's Pathway Tools.

Differentiator

Problem solved

Functional benefit

Products and services

  • Agriculture Solutions Custom digital organism models and in silico analyses for agricultural R&D clients, including crop breeding, biocontrol, biostimulant, and plant-microbe interaction use cases. Used by crop science companies, plant breeders, and biocontrol developers.
  • Industrial Biotechnology Solutions Custom digital organism models and bio-process modeling services for industrial biotech, bio-based chemicals, food ingredient, and cosmetics producers using microbial, fungal, or microalgae-based production platforms.
  • Academic Research Solutions Custom mathematical modeling and bioinformatics services for academic laboratories and public research institutions working on fundamental biology, drug discovery, plant biology, and environmental microbiology.
  • Custom Data Analyses Tailored bioinformatics workflows combining modeling, biostatistics, and bioinformatics for organizations with specific analytical needs beyond standard service offerings.
  • Digital Boost Ongoing R&D support service delivering daily dedicated modeling expertise and technical resources to client teams to reduce failure rates and accelerate bioprocess development.
  • Feasibility Study In silico feasibility analysis for biotech projects, modeling industrial scenarios to evaluate expected performance and identify bottlenecks before committing to wet-lab experimentation.

Quantifiable outcome

  • R&D failure rate reduction of up to 30% and R&D time/cost savings of up to 50% through digital boost services
  • +3 more outcomes

Companies that use iMEAN

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles2 records

iMEAN technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature8 records

iMEAN partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered major, core, flagship and minor.

  • New Wave BiotechmajorStrategic or Co-development Partner · 24 March 2026iMEAN and New Wave Biotech partner to deliver an integrated modeling workflow combining upstream and downstream bioprocess insights, accelerating scalable bioprocess development. The joint offering simplifies and accelerates the path to scalable bioprocesses.
  • Ferments du Futur ConsortiummajorStrategic or Co-development Partner · 21 January 2026iMEAN joined the Ferments du Futur consortium dedicated to advancing research and innovation in fermented foods and biopreservation. iMEAN contributes expertise in mathematical modeling and Digital FoodTech solutions to accelerate R&D for healthy, sustainable food and the One Health value chain.
  • Micropep TechnologiesmajorStrategic or Co-development Partner · 14 November 2025iMEAN and Micropep collaboration to advance sustainable agriculture by combining complementary expertise in predictive modeling and micropeptide technologies for crop protection and improvement.
  • NovobiommajorStrategic or Co-development Partner · 7 August 2023iMEAN and Novobiom (Belgian biotech startup specializing in mycoremediation) collaborate to develop innovative bioremediation solutions for soil pollutants. iMEAN provides in silico design and optimization using fungal metabolic models, while Novobiom contributes its collection of fungi and enzyme cocktails for on-site depollution.
  • INRAE (Institut national de recherche pour l'agriculture, l'alimentation et l'environnement)coreStrategic or Co-development Partner · 7 August 2023iMEAN is a spin-off of INRAE, having developed its technology during 10+ years of research at the institution. iMEAN continues to draw expertise from INRAE labs including ToxAlim (Metabolism & Xenobiotics team), LIPME, and RESTORE institute, and benefits from ongoing institutional support.
  • LimagrainflagshipStrategic or Co-development Partner · 2 June 2023The iCORN project (€2M, France 2030 funded) combines iMEAN's systems biology models with Limagrain's breeding programs to accelerate development of drought-resistant maize varieties. iMEAN builds the most advanced mechanistic model of maize to improve genomic selection. This is a flagship multi-year partnership spanning 5 years with the goal of TRL 9.
  • SRI InternationalcoreTechnology or Integration · 21 September 2022iMEAN partnered with SRI International to integrate Pathway Tools software into its service offering, enabling iMEAN customers to access in silico models via web interfaces generated by SRI's Pathway Tools. This provides complete analysis pipelines including model construction, web interface setup, and IT maintenance.
  • Puratos & LM-UGent (Laboratory of Microbiology of Ghent University)majorStrategic or Co-development Partner · 30 August 2022iMEAN leads the construction of a genomic database and web interface for 1,000 food-grade microorganisms from LM-UGent's collection for Puratos, enabling identification of enzymes and metabolic pathways for innovative food ingredients. iMEAN provided bioinformatics expertise, software development, and metabolic analysis capabilities.
  • CambriummajorStrategic or Co-development Partner · 31 January 2022iMEAN provides Cambrium (Berlin-based synthetic biology startup developing protein-based biomaterials) with advanced mathematical models to accelerate strain engineering and scale-up. Cambrium's platform combines protein engineering, ML, and lab automation, which is complemented by iMEAN's high-predictive modeling.
  • L'OréalcoreStrategic or Co-development Partner · 13 September 2021iMEAN and L'Oréal published a joint paper in ASM journal on the genome of Sphingobium xenophagum from La Roche-Posay thermal springs. iMEAN provides in silico reconstruction of exotic microorganisms and bioinformatics tools for biodiversity exploration supporting L'Oréal's thermal water research and cosmetic ingredient discovery.
  • Bayer Crop SciencecoreStrategic or Co-development Partner · 24 August 2021Bayer Crop Science partners with iMEAN to use digital organisms of plants and plant pathogens to accelerate discovery of new environmentally friendly crop protection products. iMEAN's platform extracts biological insights from Bayer's experimental data on substances and supports design of innovative chemistry at early discovery stages.
  • BIOMED AllianceminorOthers · 1 July 2021iMEAN joined BIOMED Alliance, the largest cluster of biomedical companies in Occitanie with over 80 member companies. The membership federates local actors to develop biotech business in France and across borders, with iMEAN contributing in silico tools for oncology and microbiota engineering.
  • NeoplantsmajorStrategic or Co-development Partner · 12 May 2021iMEAN set up a modeling platform for Neoplants (Parisian biotech startup developing bioengineered ornamental plants for air pollution). iMEAN designs highly predictive plant models combining complex metabolic networks and plant biology expertise to support fast and successful bioengineering projects.
  • EU Project DIVAminorStrategic or Co-development Partner · 2 April 2020iMEAN's 'Digital Seed' project was selected by EU Project DIVA for funding. The project aims to boost crop breeding through digital organisms. Over 350 SMEs applied to the DIVA Open Call with 255 proposals submitted.
  • TWB (Toulouse White Biotechnology)coreStrategic or Co-development Partner · 18 October 2018iMEAN integrates the TWB ecosystem — a pre-industrial demonstrator in industrial biotechnology (UMS under INRAE, INSA, CNRS). TWB provides wet lab capabilities (Build, Test) complementing iMEAN's dry lab modeling (Design, Learn), enabling a Design-Build-Test-Learn cycle. The partnership was strengthened in 2021 to offer a combined service from dry lab to wet lab, and iMEAN's offices are located within TWB premises.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

iMEAN competitors and assessment

Company assessment

Direct peers

  • CytoReason: Israel-based company building cell-level computational models of the human immune system for drug discovery and development. Closely comparable as a model-as-a-service platform serving enterprise biotech/pharma customers.
  • Inari Agriculture: US-based seed design company using AI and systems biology to develop high-performing crops (e.g., drought-resistant maize). Closest direct peer to iMEAN's Limagrain/iCORN work — both apply computational biology to crop improvement.

Broad incumbents

  • Codexis: Enzyme engineering company using computational and directed evolution approaches to develop industrial biocatalysts. Comparable as a computational biology company serving industrial biotech customers in pharmaceutical and food applications.
  • Insitro: Machine learning-driven drug discovery company building predictive models of disease from large-scale biological data. Comparable as a data/ML-led biology company, but focused on therapeutics rather than organism engineering.
  • Schrödinger: Computational chemistry and biology platform serving pharma and materials customers with physics-based simulation software. Comparable as a computational biology software vendor; broader scope (chemistry, materials) but similar enterprise SaaS model.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Comparable as a large-scale computational biology platform, though focused on pharma rather than industrial biotech and agriculture.
  • Ginkgo Bioworks: US-based organism engineering platform offering end-to-end synthetic biology services across industrial, ag, and pharma. Larger, broader offering than iMEAN's focused metabolic-modeling services, but overlapping on organism design and strain engineering.
  • Amyris: Synthetic biology company engineering yeast strains for sustainable ingredient production. Comparable as a synbio company applying computational biology to industrial strain engineering, though now restructured and focused on ingredients.

Emerging players

  • TeselaGen: Synthetic biology platform combining AI with lab automation for DNA design and strain engineering workflows. Comparable as a bioinformatics/informatics platform for synbio customers, though more focused on DNA construct design.
  • Benchling: Cloud-based platform for biology R&D with LIMS, ELN, and molecular biology tools. Comparable as a life science informatics platform for biotech R&D teams, though broader and more horizontal than iMEAN's modeling-specific offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

iMEAN social profiles

Digital presence

iMEAN financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iMEAN leadership team

Management profile

Number of profiles

Profiles1 record

iMEAN funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iMEAN M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iMEAN

What does iMEAN do?

iMEAN builds genome-scale mathematical models ("digital organisms") of living cells — bacteria, fungi, yeast, microalgae, and plants — using constraint-based modeling, multi-omics integration, regulatory network inference, and kinetics modeling. It sells these models together with feasibility studies, organism design, consortia design, and ongoing Digital Boost R&D support to industrial biotech, agriculture, cosmetics, food, and academic clients via project-based engagements.

Is iMEAN a public or private company?

iMEAN is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was iMEAN founded?

iMEAN was founded in 2018. It employs 11 to 50 people.

Where is iMEAN based?

iMEAN is headquartered in Toulouse, France, in the Europe region.

How does iMEAN make money?

Three revenue lines are on record. Project-Based R&D Services are the primary driver. The others are digital Organism Licensing / Model Delivery and software and Web Platform Services.

Who are iMEAN's main competitors?

Direct peers on record are CytoReason and Inari Agriculture. Broad incumbents are Codexis, Insitro, Schrödinger, Recursion Pharmaceuticals, Ginkgo Bioworks and Amyris. Emerging players are TeselaGen and Benchling.

Does iMEAN have an API?

No public API is recorded for iMEAN.

What industry is iMEAN in?

iMEAN's product category is Computational Biology Services. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals